story of the week
Eribulin Mesylate Administered Biweekly in Patients With HER2- Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Breast Cancer